dihydronarciclasine

isolated from Zephyranthes candida; structure given in first source; RN given refers to (2S-(2alpha,3beta,4beta,4abeta,11balpha))-isomer

Also Known As:

dihydronarciclasine, (2S-(2alpha,3beta,4beta,4abeta,11bbeta))-isomer; trans-dihydronarciclasine

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Alkaloids: 5398
  - dihydronarciclasine: 5

Experts

1.	Hegedűs, László: 1 article (07/2019)
2.	Kádas, István: 1 article (07/2019)
3.	Pogrányi, Balázs: 1 article (07/2019)
4.	Pálchuber, Péter: 1 article (07/2019)
5.	Simon, András: 1 article (07/2019)
6.	Varró, Gábor: 1 article (07/2019)
7.	Cho, Cheon-Gyu: 1 article (10/2012)
8.	Kim, Byoung Kook: 1 article (10/2012)
9.	Kim, Eun Shil: 1 article (10/2012)
10.	Kim, Ju Young: 1 article (10/2012)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2012 - "(±) trans-Dihydronarciclasine, isolated from Chinese medicinal plant Zephyranthes candida, has been shown to possess quite potent anti-tumoral effect against selected human cancer cell lines. " 01/28/2011 - "Human cytochrome P450 liability studies of trans-dihydronarciclasine: a readily available, potent, and selective cancer cell growth inhibitor." 07/01/2009 - "Synthesis of the strong cancer cell growth inhibitors trans-dihydronarciclasine and 7-deoxy-trans-dihydronarciclasine (1a)." 07/01/2019 - "A series of (±)-trans-dihydronarciclasine and (±)-trans-dihydrolycoricidine derivatives with variously substituted ring A was synthesised and evaluated for their antiproliferative activity against 60 human tumour cell lines (NCI60), representing leukemia, melanoma, and cancers of the lung, colon, brain, ovary, breast, prostate, as well as kidney in vitro. "
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/01/2012 - "However, little is known about the anti-tumoral effect of (±) trans-dihydronarciclasine in acute myeloid leukemia (AML). " 10/01/2012 - "Anti-leukemic effect of a synthetic compound, (±) trans-dihydronarciclasine (HYU-01) via cell-cycle arrest and apoptosis in acute myeloid leukemia."
3.	Melanoma (Melanoma, Malignant) 07/01/2019 - "A series of (±)-trans-dihydronarciclasine and (±)-trans-dihydrolycoricidine derivatives with variously substituted ring A was synthesised and evaluated for their antiproliferative activity against 60 human tumour cell lines (NCI60), representing leukemia, melanoma, and cancers of the lung, colon, brain, ovary, breast, prostate, as well as kidney in vitro. "
4.	Lymphoid Leukemia 01/01/1990 - "Separation of a n-BuOH extract directed by results of a bioassay employing the P-388 lymphocytic leukemia led to trans-dihydronarciclasine [2] as the principal cytostatic agent with ED50 3.2 X 10(-3) micrograms/ml."
5.	Leukemia 07/01/2019 - "A series of (±)-trans-dihydronarciclasine and (±)-trans-dihydrolycoricidine derivatives with variously substituted ring A was synthesised and evaluated for their antiproliferative activity against 60 human tumour cell lines (NCI60), representing leukemia, melanoma, and cancers of the lung, colon, brain, ovary, breast, prostate, as well as kidney in vitro. "

Related Drugs and Biologics

1.	Growth Inhibitors
2.	Cytochrome P-450 Enzyme System (Cytochrome P450)
3.	Cytostatic Agents
4.	trans-dihydrolycoricidine
5.	7-deoxy-trans-dihydronarciclasine